Structure Therapeutics (NASDAQ:GPCR) Hits New 52-Week Low – Time to Sell?

Structure Therapeutics Inc. (NASDAQ:GPCR)’s stock price reached a new 52-week low during mid-day trading on Tuesday . The company traded as low as $19.60 and last traded at $19.71, with a volume of 41866 shares trading hands. The stock had previously closed at $20.16.

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on GPCR shares. JMP Securities reiterated a “market outperform” rating and set a $91.00 price objective on shares of Structure Therapeutics in a research note on Wednesday, December 18th. Stifel Nicolaus started coverage on Structure Therapeutics in a research note on Wednesday, January 8th. They set a “buy” rating and a $50.00 price objective on the stock. HC Wainwright reiterated a “buy” rating and set a $80.00 price objective on shares of Structure Therapeutics in a research note on Thursday, December 19th. Finally, William Blair assumed coverage on Structure Therapeutics in a research note on Friday, February 28th. They set an “outperform” rating on the stock. Eight investment analysts have rated the stock with a buy rating, According to MarketBeat.com, Structure Therapeutics currently has a consensus rating of “Buy” and a consensus price target of $81.29.

Structure Therapeutics Stock Performance

The stock has a market cap of $1.23 billion, a P/E ratio of -28.95 and a beta of -2.35. The firm has a 50-day moving average price of $25.60 and a 200-day moving average price of $32.66.

Structure Therapeutics (NASDAQ:GPCR) last announced its earnings results on Thursday, February 27th. The company reported ($0.22) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.23) by $0.01. On average, research analysts predict that Structure Therapeutics Inc. will post -0.82 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in GPCR. Deep Track Capital LP increased its position in Structure Therapeutics by 129.4% during the 4th quarter. Deep Track Capital LP now owns 2,800,000 shares of the company’s stock valued at $75,936,000 after buying an additional 1,579,492 shares in the last quarter. Point72 Asset Management L.P. increased its position in Structure Therapeutics by 196.5% during the 3rd quarter. Point72 Asset Management L.P. now owns 1,238,268 shares of the company’s stock valued at $54,348,000 after buying an additional 820,589 shares in the last quarter. Janus Henderson Group PLC increased its position in Structure Therapeutics by 18.0% during the 3rd quarter. Janus Henderson Group PLC now owns 3,956,878 shares of the company’s stock valued at $173,623,000 after buying an additional 602,609 shares in the last quarter. Vestal Point Capital LP boosted its stake in Structure Therapeutics by 105.4% during the 3rd quarter. Vestal Point Capital LP now owns 1,150,000 shares of the company’s stock valued at $50,474,000 after purchasing an additional 590,000 shares during the last quarter. Finally, Boxer Capital Management LLC purchased a new stake in Structure Therapeutics during the 4th quarter valued at $13,560,000. Institutional investors own 91.78% of the company’s stock.

About Structure Therapeutics

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.